Pacific Biosciences of California, Inc. PACB
Set alert
2.35 USD -0.26 -9.98%
At close
2.39 +0.04 +1.92%
Pre-market · Nov 3, 4:00 AM ET
2.31 Day range 2.72
1.07 52-week range 3.44
- YTD
- +25.40%
- 1 year
- +0.21%
- Open
- 2.68
- Prev close
- 2.61
- Mkt cap
- 728.90M
- Vol
- 9.10M
- Avg vol
- 12.02M
- EPS
- -0.43
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.31
- High
- 2.72
- Forward P/E
- -2.84
- Beta
- 2.01
- Short ratio
- 4.46
- Inst. own
- 84.53%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.01
- 200-d avg
- 2.02
- 1y target
- 3.02
5D chart
Signals (85)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Nov 2, 3:40 PM | 13 hours ago |
| MACD: Sell Signal | Nov 2, 3:30 PM | 13 hours ago |
| SMA: Bearish | Nov 2, 3:20 PM | 13 hours ago |
| SMA: Bearish | Nov 2, 3:20 PM | 13 hours ago |
| SMA: Bullish | Nov 2, 3:15 PM | 14 hours ago |
| MACD: Buy Signal | Nov 2, 2:50 PM | 14 hours ago |
| MACD: Sell Signal | Nov 2, 2:45 PM | 14 hours ago |
| SMA: Bearish | Nov 2, 2:30 PM | 14 hours ago |
| SMA: Bullish | Nov 2, 2:05 PM | 15 hours ago |
| MACD: Buy Signal | Nov 2, 2:05 PM | 15 hours ago |
| MACD: Sell Signal | Nov 2, 1:40 PM | 15 hours ago |
| MACD: Buy Signal | Nov 2, 1:15 PM | 16 hours ago |
| MACD: Sell Signal | Nov 2, 1:10 PM | 16 hours ago |
| MACD: Buy Signal | Nov 2, 1:00 PM | 16 hours ago |
| MACD: Sell Signal | Nov 2, 12:40 PM | 16 hours ago |
| SMA: Bullish | Nov 2, 12:05 PM | 17 hours ago |
| MACD: Buy Signal | Nov 2, 12:05 PM | 17 hours ago |
| MACD: Sell Signal | Nov 2, 11:55 AM | 17 hours ago |
| SMA: Bearish | Nov 2, 11:45 AM | 17 hours ago |
| MACD: Buy Signal | Nov 2, 11:40 AM | 17 hours ago |
Newest 20 of 85.
Analyst view
Consensus: buy
Buy
Price target (mean) 3.02 +28.8% upside
Now 2.35
- Target (low)
- 2.00
- Target (mean)
- 3.02
- Target (high)
- 6.00
Ratings (0m) 15 7 buy · 8 hold · 0 sell
- Strong buy1
- Buy6
- Hold8
- Sell0
- Strong sell0
Recommendation trend
- This month 15
- 1 month ago 15
- 2 months ago 14
- 3 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.17551 | -0.21 – -0.11 | -0.27 | +35.0% | 40.66M | -30.3% | 11 |
| Next quarter | -0.15903 | -0.19227 – -0.13 | -0.26 | +38.8% | 42.54M | +9.6% | 8 |
| Current year | -0.81244 | -0.89123 – -0.74 | -1.11 | +26.8% | 155.49M | -22.5% | 12 |
| Next year | -0.63882 | -0.74484 – -0.54 | -0.81244 | +21.4% | 191.23M | +23.0% | 12 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | UBS | Downgrade | Buy | Neutral |
| Nov 11, 2024 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Nov 11, 2024 | Piper Sandler | Maintained | Neutral | Neutral |
| Aug 28, 2024 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Aug 13, 2024 | Stephens & Co. | Maintained | Overweight | Overweight |
| Aug 12, 2024 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Aug 8, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Aug 8, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 3, 2024 | Jefferies | Initiated | — | Buy |
| May 15, 2024 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| May 13, 2024 | Piper Sandler | Maintained | Neutral | Neutral |
| May 10, 2024 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Apr 22, 2024 | JP Morgan | Downgrade | Overweight | Neutral |
| Apr 19, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |
| Apr 18, 2024 | Bernstein | Maintained | Outperform | Outperform |
| Apr 18, 2024 | Goldman Sachs | Downgrade | Buy | Neutral |
| Apr 18, 2024 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Apr 17, 2024 | TD Cowen | Maintained | Buy | Buy |
| Apr 10, 2024 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Apr 10, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| Mar 22, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Feb 16, 2024 | UBS | Maintained | Buy | Buy |
| Dec 14, 2023 | Guggenheim | Initiated | — | Neutral |
| Dec 14, 2023 | Stephens & Co. | Initiated | — | Overweight |
| Dec 13, 2023 | Wolfe Research | Initiated | — | Peer Perform |
| Nov 17, 2023 | UBS | Upgrade | Neutral | Buy |
| Nov 6, 2023 | Piper Sandler | Maintained | Neutral | Neutral |
| Oct 31, 2023 | Canaccord Genuity | Maintained | Buy | Buy |
| Oct 31, 2023 | Cantor Fitzgerald | Upgrade | Neutral | Overweight |
| Oct 24, 2023 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |